290 related articles for article (PubMed ID: 27613470)
1. Omalizumab and allergen immunotherapy in a patient with asthma and inhaled corticosteroid-induced adrenal suppression.
Forbush JT; Banks TA
Ann Allergy Asthma Immunol; 2016 Sep; 117(3):335-7. PubMed ID: 27613470
[No Abstract] [Full Text] [Related]
2. The relationship between allergen immunotherapy and omalizumab for treating asthma.
Braido F; Corsico A; Rogkakou A; Ronzoni V; Baiardini I; Canonica GW
Expert Rev Respir Med; 2015 Apr; 9(2):129-34. PubMed ID: 25578528
[TBL] [Abstract][Full Text] [Related]
3. Omalizumab Is Equally Effective in Persistent Allergic Oral Corticosteroid-Dependent Asthma Caused by Either Seasonal or Perennial Allergens: A Pilot Study.
Domingo C; Pomares X; Navarro A; Rudi N; Sogo A; Dávila I; Mirapeix RM
Int J Mol Sci; 2017 Feb; 18(3):. PubMed ID: 28264494
[TBL] [Abstract][Full Text] [Related]
4. Preseasonal treatment with either omalizumab or an inhaled corticosteroid boost to prevent fall asthma exacerbations.
Teach SJ; Gill MA; Togias A; Sorkness CA; Arbes SJ; Calatroni A; Wildfire JJ; Gergen PJ; Cohen RT; Pongracic JA; Kercsmar CM; Khurana Hershey GK; Gruchalla RS; Liu AH; Zoratti EM; Kattan M; Grindle KA; Gern JE; Busse WW; Szefler SJ
J Allergy Clin Immunol; 2015 Dec; 136(6):1476-1485. PubMed ID: 26518090
[TBL] [Abstract][Full Text] [Related]
5. Timing is everything: Targeting IgE to reduce asthma exacerbation risk.
O'Byrne PM; Tworek D
J Allergy Clin Immunol; 2015 Dec; 136(6):1486-1487. PubMed ID: 26654197
[No Abstract] [Full Text] [Related]
6. [Omalizumab and allergen immunotherapy: A clinical report and review of the literature].
Carrier C; Demoly P; Caimmi D
Rev Mal Respir; 2019 Feb; 36(2):191-196. PubMed ID: 30396780
[TBL] [Abstract][Full Text] [Related]
7. Anaphylaxis to Mepolizumab and Omalizumab in a Single Patient: Is Polysorbate the Culprit?
Bergmann KC; Maurer M; Church MK; Zuberbier T
J Investig Allergol Clin Immunol; 2020 Aug; 30(4):285-287. PubMed ID: 32723701
[No Abstract] [Full Text] [Related]
8. Impact of omalizumab on emergency-department visits, hospitalizations, and corticosteroid use among patients with uncontrolled asthma.
Lafeuille MH; Dean J; Zhang J; Duh MS; Gorsh B; Lefebvre P
Ann Allergy Asthma Immunol; 2012 Jul; 109(1):59-64. PubMed ID: 22727159
[TBL] [Abstract][Full Text] [Related]
9. Assessment of sublingual immunotherapy efficacy in children with house dust mite-induced allergic asthma optimally controlled by pharmacologic treatment and mite-avoidance measures.
Pham-Thi N; Scheinmann P; Fadel R; Combebias A; Andre C
Pediatr Allergy Immunol; 2007 Feb; 18(1):47-57. PubMed ID: 17295799
[TBL] [Abstract][Full Text] [Related]
10. Who (if anyone) actually gets steroid-sparing effects from aeroallergen immunotherapy?
Adkinson NF
J Allergy Clin Immunol; 2010 Nov; 126(5):950-1. PubMed ID: 21050943
[No Abstract] [Full Text] [Related]
11. Evaluation of long-term safety and efficacy of omalizumab in elderly patients with uncontrolled allergic asthma.
Tat TS; Cilli A
Ann Allergy Asthma Immunol; 2016 Nov; 117(5):546-549. PubMed ID: 27788886
[TBL] [Abstract][Full Text] [Related]
12. Omalizumab's Impact on Total and Allergen-Specific IgE Levels: A Polyclonal Story.
Eckl-Dorna J
Int Arch Allergy Immunol; 2016; 169(2):69-70. PubMed ID: 27035498
[No Abstract] [Full Text] [Related]
13. Progressive clinical effects of the combination omalizumab and HDM - allergen immunotherapy in asthma.
Bozek A; Rogala B; Miodonska M; Canonica GW
J Asthma; 2024 Jun; 61(6):532-538. PubMed ID: 38064236
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of omalizumab in asthmatic patients with IgE levels above 700 IU/mL: a retrospective study.
Maselli DJ; Singh H; Diaz J; Peters JI
Ann Allergy Asthma Immunol; 2013 Jun; 110(6):457-61. PubMed ID: 23706716
[TBL] [Abstract][Full Text] [Related]
15. Strategies to reduce corticosteroid-related adverse events in asthma.
Heffler E; Bagnasco D; Canonica GW
Curr Opin Allergy Clin Immunol; 2019 Feb; 19(1):61-67. PubMed ID: 30407207
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of leukotriene receptor antagonists and synthesis inhibitors in asthma.
O'Byrne PM; Gauvreau GM; Murphy DM
J Allergy Clin Immunol; 2009 Sep; 124(3):397-403. PubMed ID: 19608262
[TBL] [Abstract][Full Text] [Related]
17. Influence of Omalizumab on Allergen-Specific IgE in Patients with Adult Asthma.
Mizuma H; Tanaka A; Uchida Y; Fujiwara A; Manabe R; Furukawa H; Kuwahara N; Fukuda Y; Kimura T; Jinno M; Ohta S; Yamamoto M; Matsukura S; Adachi M; Sagara H
Int Arch Allergy Immunol; 2015; 168(3):165-72. PubMed ID: 26790100
[TBL] [Abstract][Full Text] [Related]
18. Omalizumab effectively protects against early and late allergic responses in asthma after 4 weeks.
Trischler J; Lieb A; Arnold M; Schulze J; Rosewich M; Schubert R; Bottoli I; Zielen S
Allergy; 2017 Dec; 72(12):1912-1915. PubMed ID: 28581121
[TBL] [Abstract][Full Text] [Related]
19. The effect of omalizumab on eosinophilic inflammation of the respiratory tract in patients with allergic asthma.
Kupryś-Lipińska I; Molińska K; Kuna P
Pneumonol Alergol Pol; 2016; 84(4):232-43. PubMed ID: 27435350
[TBL] [Abstract][Full Text] [Related]
20. What is the evidence for different management options for difficult to treat severe asthma?
Drug and Therapeutics Bulletin
BMJ; 2017 Aug; 358():j3403. PubMed ID: 28807925
[No Abstract] [Full Text] [Related]
[Next] [New Search]
